Expertise in
17
conditions

Dr. Loren K. Mell

Radiation Oncology
UCSD Heath Care
3855 Health Sciences Dr, 
La Jolla, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
17
conditions
UCSD Heath Care
3855 Health Sciences Dr, 
La Jolla, CA 

Overview

Loren Mell is a Radiation Oncologist practicing medicine in La Jolla, California.

Dr. Mell is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Cervical Cancer, Adenoid Cystic Carcinoma, and Throat Cancer.

He is actively involved in clinical research, co-authoring 170 peer reviewed articles and participating in 19 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in CA

Hospital Affiliations

Uc San Diego Health Hillcrest - Hillcrest Med Ctr

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Net

Accepted plan types not found. Please verify directly with the provider.

HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

UCSD Heath Care
3855 Health Sciences Dr, La Jolla, CA 92093
Other Locations
Pet/Ct Center At Uc San Diego Health
3960 Health Sciences Dr, La Jolla, CA 92037

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: August 27, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Suspended
Publish Date: June 25, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2/Phase 3
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Peposertib
Study Phase: Phase 1
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: May 27, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: May 22, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2026
Intervention Type: Radiation, Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

169 Total Publications

Androgen Deprivation Therapy (ADT) and Radiotherapy (RT) with Imaging Evaluation Longitudinally (ARIEL) trial: protocol, early results, and implications of neoadjuvant ADT for focal RT boost in prostate cancer.
Androgen Deprivation Therapy (ADT) and Radiotherapy (RT) with Imaging Evaluation Longitudinally (ARIEL) trial: protocol, early results, and implications of neoadjuvant ADT for focal RT boost in prostate cancer.
Journal: medRxiv : the preprint server for health sciences
Published: May 07, 2026
Similar Doctors
Expertise in
8
conditions
Dr. Jyoti S. Mayadev
Radiation Oncology
Expertise in
8
conditions
Dr. Jyoti S. Mayadev
Radiation Oncology
Referral may be required

UCSD Heath Care

3855 Health Sciences Dr, 
La Jolla, CA 
 (0.1 miles away)
800-926-8273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jyoti Mayadev is a Radiation Oncologist practicing medicine in La Jolla, California. Dr. Mayadev is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Cervical Cancer, Vulvar Cancer, Neuroendocrine Carcinoma of the Cervix, Endometrial Cancer, and Lymphadenectomy.

Expertise in
21
conditions
Dr. Jona A. Hattangadi-Gluth
Radiation Oncology
Expertise in
21
conditions
Dr. Jona A. Hattangadi-Gluth
Radiation Oncology
Referral may be required

UCSD Heath Care

3855 Health Sciences Dr, 
La Jolla, CA 
 (0.1 miles away)
858-822-6040
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jona Hattangadi-Gluth is a Radiation Oncologist practicing medicine in La Jolla, California. Dr. Hattangadi-Gluth is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Brain Tumor, Arteriovenous Malformation, Vein of Galen Aneurysm, and Wyburn-Mason Syndrome.

Expertise in
8
conditions
Dr. Brent S. Rose
Radiation Oncology
Expertise in
8
conditions
Dr. Brent S. Rose
Radiation Oncology
Referral may be required

UCSD Heath Care

3855 Health Sciences Dr, 
La Jolla, CA 
 (0.1 miles away)
619-341-3899
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Brent Rose is a Radiation Oncologist practicing medicine in La Jolla, California. Dr. Rose is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Anal Cancer, Prostatectomy, and Orchiectomy.

Frequently Asked Questions about Dr. Loren K. Mell

How do I make an appointment with Dr. Loren K. Mell?

You can book an appointment with Dr. Loren K. Mell by calling their office at 858-822-6040. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Loren K. Mell a top-rated expert for Head and Neck Squamous Cell Carcinoma (HNSCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Loren K. Mell is classified as an Distinguished expert for Head and Neck Squamous Cell Carcinoma (HNSCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Loren K. Mell specialize in?

While Dr. Loren K. Mell is a Radiation Oncology, they have specific expertise in Head and Neck Squamous Cell Carcinoma (HNSCC), Cervical Cancer, and Adenoid Cystic Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Loren K. Mell participate in research or clinical trials?

Yes. Dr. Loren K. Mell has published 169 articles and abstracts on conditions like Head and Neck Squamous Cell Carcinoma (HNSCC). You can view a list of Dr. Loren K. Mell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Loren K. Mell accept my insurance?

Dr. Loren K. Mell accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 858-822-6040 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mell's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 47 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile